<DOC>
	<DOCNO>NCT01008995</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( good bad effect ) safety ustekinumab treatment patient moderate severe psoriasis China .</brief_summary>
	<brief_title>A Study Safety Effectiveness Ustekinumab ( Stelara ) Chinese Patients With Psoriasis</brief_title>
	<detailed_description>In study , 220 patient divide two group randomly ( chance ) , like flip coin . Each group receive different treatment . The result group compare . There 2 treatment group study , Group 1 Group 2 . Group 1 receive placebo Weeks 0 4 , ustekinumab 45 mg Weeks 12 16 . Group 2 receive ustekinumab 45 mg Weeks 0 , 4 , 16 placebo Week 12 . All patient study eventually receive ustekinumab Week 12 . The patient study 36 week , study visit approximately 10 time . Effectiveness evaluation conduct throughout study include Psoriasis Area Severity Index ( PASI ) , Physician 's Global Assessment ( PGA ) Dermatology Life Quality Index ( DLQI ) . Safety assessment also perform throughout study include obtain evaluate laboratory test , vital sign ( e.g. , blood pressure ) occurrence severity adverse event . GROUP 1 : Placebo Weeks 0 4 , ustekinumab 45 mg Weeks 12 16 . GROUP 2 : Ustekinumab 45 mg Weeks 0 , 4 , 16 . Placebo Week 12</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Must Chinese ancestry Have diagnosis plaquetype psoriasis least 6 month prior study start Have plaquetype psoriasis cover least 10 % total BSA screening time study start Have Psoriasis Area Severity Index ( PASI ) score 12 great study start Must candidate phototherapy systemic treatment psoriasis ( either naive history previous treatment ) Currently nonplaque form psoriasis Have current druginduced psoriasis Have use investigational drug within previous 4 week Have use biologic within previous 3 month Be know infected human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , syphilis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>asian patient</keyword>
	<keyword>Chinese</keyword>
	<keyword>ustekinumab</keyword>
	<keyword>CNTO 1275</keyword>
	<keyword>Stelara</keyword>
</DOC>